Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer

BACKGROUND: The addition of anti-human epidermal growth factor receptor 2 (HER2)-targeted drugs, such as trastuzumab, lapatinib, and trastuzumab emtansine (T-DM1), to chemotherapy significantly improved prognosis of HER2-positive breast cancer patients. However, it was confused that metastatic patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Qing, Qi, Fan, Bian, Li, Zhang, Shao-Hua, Wang, Tao, Jiang, Ze-Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339924/
https://www.ncbi.nlm.nih.gov/pubmed/28229982
http://dx.doi.org/10.4103/0366-6999.200542

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339924/
https://www.ncbi.nlm.nih.gov/pubmed/28229982
http://dx.doi.org/10.4103/0366-6999.200542

Ejemplares similares